TEC-话题@MedSci

#TEC#

484篇内容 | 2343人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652536, encodeId=5fd9165253698, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, objectType=article, longId=736911, objectId=1981e36911b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1981e36911b5, replyNumber=0, likeNumber=51, createdTime=2022-09-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1981e36911b5, moduleTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1981e36911b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652540, encodeId=49e01652540b1, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotech：一次生产10亿CAR-T细胞，新型CRISPR技术，无需病毒载体高效插入超长DNA序列, objectType=article, longId=739036, objectId=f1d8e3903613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1d8e3903613, replyNumber=0, likeNumber=44, createdTime=2023-03-31, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1d8e3903613, moduleTitle=Nat Biotech：一次生产10亿CAR-T细胞，新型CRISPR技术，无需病毒载体高效插入超长DNA序列, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1d8e3903613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652532, encodeId=eff916525323d, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=NEJM：特考韦瑞（Tecovirimat）和猴痘的治疗——过去、现在和未来的考量, objectType=article, longId=734855, objectId=ef64e34855c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef64e34855c6, replyNumber=0, likeNumber=43, createdTime=2023-04-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef64e34855c6, moduleTitle=NEJM：特考韦瑞（Tecovirimat）和猴痘的治疗——过去、现在和未来的考量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef64e34855c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652544, encodeId=15611652544f6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, objectType=article, longId=739304, objectId=992ee39304e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=992ee39304e3, replyNumber=0, likeNumber=59, createdTime=2023-07-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=992ee39304e3, moduleTitle=BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=992ee39304e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652521, encodeId=b1e116525215b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, objectType=article, longId=301648, objectId=93a0301648a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a0301648a6, replyNumber=0, likeNumber=55, createdTime=2022-12-11, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a0301648a6, moduleTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a0301648a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652537, encodeId=e123165253e59, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle= Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌, objectType=article, longId=737316, objectId=0e77e37316b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e77e37316b6, replyNumber=0, likeNumber=46, createdTime=2023-04-19, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e77e37316b6, moduleTitle= Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e77e37316b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652531, encodeId=1ccd1652531a9, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Biotechnology：调控蛋白质稳态，司龙龙团队建立PROTAC减毒疫苗新策略, objectType=article, longId=731364, objectId=6c56e31364d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c56e31364d4, replyNumber=0, likeNumber=42, createdTime=2023-03-30, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c56e31364d4, moduleTitle=Nature Biotechnology：调控蛋白质稳态，司龙龙团队建立PROTAC减毒疫苗新策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c56e31364d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652524, encodeId=1c4d165252455, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, objectType=article, longId=724120, objectId=4f46e241201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f46e241201a, replyNumber=0, likeNumber=47, createdTime=2023-01-31, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f46e241201a, moduleTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f46e241201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652526, encodeId=ae5d16525266c, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Nanotechnology：厦门大学刘刚团队开发新型纳米囊泡疫苗平台，可介导超强抗肿瘤免疫活性, objectType=article, longId=724588, objectId=b32fe2458803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b32fe2458803, replyNumber=0, likeNumber=42, createdTime=2022-07-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b32fe2458803, moduleTitle=Nature Nanotechnology：厦门大学刘刚团队开发新型纳米囊泡疫苗平台，可介导超强抗肿瘤免疫活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b32fe2458803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652534, encodeId=93e6165253461, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, objectType=article, longId=735741, objectId=dd07e3574140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd07e3574140, replyNumber=0, likeNumber=60, createdTime=2023-01-26, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd07e3574140, moduleTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd07e3574140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652519, encodeId=2b04165251908, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, objectType=article, longId=300761, objectId=3b82300e6134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b82300e6134, replyNumber=0, likeNumber=55, createdTime=2022-08-28, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b82300e6134, moduleTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b82300e6134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652543, encodeId=eda2165254384, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol：利用1毫升血液诊断癌症，精确度高达92%, objectType=article, longId=739136, objectId=926ae3913658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=926ae3913658, replyNumber=0, likeNumber=56, createdTime=2022-10-24, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=926ae3913658, moduleTitle=Nat Biotechnol：利用1毫升血液诊断癌症，精确度高达92%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=926ae3913658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652533, encodeId=a09a16525337e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Nanotechnol：突破！把血压计“纹”在身上，全天候监测并预警高血压危象, objectType=article, longId=735377, objectId=bb93e35377c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb93e35377c1, replyNumber=0, likeNumber=50, createdTime=2023-04-23, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb93e35377c1, moduleTitle=Nature Nanotechnol：突破！把血压计“纹”在身上，全天候监测并预警高血压危象, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb93e35377c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652541, encodeId=4e7d1652541de, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, objectType=article, longId=739074, objectId=6781e3907456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781e3907456, replyNumber=0, likeNumber=57, createdTime=2023-04-27, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781e3907456, moduleTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781e3907456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652507, encodeId=01b8165250e7e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Nanotechnology：惊呆了，癌细胞学会了三十六计，釜底抽薪，偷走免疫细胞的线粒体，实现免疫逃逸, objectType=article, longId=221090, objectId=304122109079, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=304122109079, replyNumber=0, likeNumber=41, createdTime=2022-06-17, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=304122109079, moduleTitle=Nature Nanotechnology：惊呆了，癌细胞学会了三十六计，釜底抽薪，偷走免疫细胞的线粒体，实现免疫逃逸, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=304122109079)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652538, encodeId=17b6165253874, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, objectType=article, longId=737431, objectId=c616e3743158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c616e3743158, replyNumber=0, likeNumber=44, createdTime=2022-12-17, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c616e3743158, moduleTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c616e3743158)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652516, encodeId=55461652516b1, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌, objectType=article, longId=295543, objectId=761e29554381, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=761e29554381, replyNumber=0, likeNumber=51, createdTime=2022-11-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=761e29554381, moduleTitle=NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=761e29554381)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652542, encodeId=3c3f1652542ff, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=55, createdTime=2022-11-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652509, encodeId=4e3e165250926, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotech：刘如谦推出先导编辑2.0，让复杂遗传病的治疗成为可能, objectType=article, longId=265045, objectId=6312265045d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6312265045d0, replyNumber=0, likeNumber=38, createdTime=2022-08-30, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6312265045d0, moduleTitle=Nat Biotech：刘如谦推出先导编辑2.0，让复杂遗传病的治疗成为可能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6312265045d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652530, encodeId=e51d1652530ee, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Biotechnology：深度视觉蛋白质组学：对单个癌细胞空间表征，发现癌症治疗新靶点, objectType=article, longId=727872, objectId=2330e27872ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2330e27872ac, replyNumber=0, likeNumber=47, createdTime=2022-06-25, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2330e27872ac, moduleTitle=Nature Biotechnology：深度视觉蛋白质组学：对单个癌细胞空间表征，发现癌症治疗新靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2330e27872ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TEC

2020-05-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）

2022-09-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotech：一次生产10亿CAR-T细胞，新型CRISPR技术，无需病毒载体高效插入超长DNA序列

2023-03-31

shock_melon (审核中...)

前往app查看评论内容

#TEC#

NEJM：特考韦瑞（Tecovirimat）和猴痘的治疗——过去、现在和未来的考量

2023-04-13

shock_melon (审核中...)

前往app查看评论内容

#TEC#

BioNTech的mRNA疫苗联合CAR-T治疗实体瘤临床效果下降，但对睾丸癌效果亮眼

2023-07-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌

2022-12-11

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌

2023-04-19

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Biotechnology：调控蛋白质稳态，司龙龙团队建立PROTAC减毒疫苗新策略

2023-03-30

shock_melon (审核中...)

前往app查看评论内容

#TEC#

AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切

2023-01-31

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Nanotechnology：厦门大学刘刚团队开发新型纳米囊泡疫苗平台，可介导超强抗肿瘤免疫活性

2022-07-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤

2023-01-26

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售

2022-08-28

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol：利用1毫升血液诊断癌症，精确度高达92%

2022-10-24

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Nanotechnol：突破！把血压计“纹”在身上，全天候监测并预警高血压危象

2023-04-23

shock_melon (审核中...)

前往app查看评论内容

#TEC#

ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）

2023-04-27

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Nanotechnology：惊呆了，癌细胞学会了三十六计，釜底抽薪，偷走免疫细胞的线粒体，实现免疫逃逸

2022-06-17

shock_melon (审核中...)

前往app查看评论内容

#TEC#

J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌

2022-12-17

shock_melon (审核中...)

前往app查看评论内容

#TEC#

NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌

2022-11-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2022-11-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotech：刘如谦推出先导编辑2.0，让复杂遗传病的治疗成为可能

2022-08-30

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Biotechnology：深度视觉蛋白质组学：对单个癌细胞空间表征，发现癌症治疗新靶点

2022-06-25

科室
- - 订阅+
  - 更多科室
工具
服务